Astellas Pharma is a pharmaceutical company focused on the development of drugs and medical solutions. Its focus areas include urology, immunology, cardiology, infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system. Astellas Pharma's main products include XTANDI, an androgen receptor signaling inhibitor indicated for the treatment of forms of advanced prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation-positive; PADCEV, a treatment for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); Evrenzo, an oral treatment for anemia associated with chronic kidney disease (CKD), and Prograf and Advagraf/Graceptor/ASTAGRAF, immunosuppressants used to suppress organ rejection following a transplant.
Gross profit (H1, 2021)
Gross profit margin (H1, 2021), %
Net income (H1, 2021)
EBIT (H1, 2021)
Market capitalization (21-Jul-2021)
Closing stock price (21-Jul-2021)
|JPY||Q1, 2019||Q2, 2019||Q3, 2019||Q1, 2020||Q2, 2020||Q3, 2020||Q1, 2021||Q2, 2021|
Depreciation and Amortization
Cash From Operating Activities
|Company Name||Date||Deal Size|
|Iota Biosciences||October 15, 2020||$127.5 m|
|Nanna Therapeutics||April 21, 2020||£12 m|
|Xyphos||December 26, 2019|
|Audentes Therapeutics||December 02, 2019||$3 b|
|Potenza Therapeutics||December 14, 2018||$405 m|
|Quethera||August 14, 2018||£85 m|
|Universal Cells Inc.||February 13, 2018|
|Mitobridge||December 01, 2017|
|Ogeda||April 02, 2017||€500 m|
|Ganymed Pharmaceuticals||October 28, 2016||$1.4 b|
Astellas Pharma revenue breakdown by business segment: 30.7% from XTANDI, 14.8% from Prograf, 12.4% from Betanis/Myrbetriq/BETMIGA and 42.0% from Other
Astellas Pharma revenue breakdown by geographic segment: 34.4% from United States , 28.8% from Japan and 36.7% from Other
Astellas Pharma has 50.39k Twitter Followers. The number of followers has increased 0.6% month over month and increased 2.6% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Astellas Pharma founded?
Astellas Pharma was founded in 1923.
Who are Astellas Pharma key executives?
Astellas Pharma's key executives are Yoshihiko Hatanaka, Shontelle Dodson and Kenji Yasukawa.
How many employees does Astellas Pharma have?
Astellas Pharma has 15,883 employees.
What is Astellas Pharma revenue?
Latest Astellas Pharma annual revenue is ¥1.3 t.
What is Astellas Pharma revenue per employee?
Latest Astellas Pharma revenue per employee is ¥81.9 m.
Who are Astellas Pharma competitors?
Competitors of Astellas Pharma include Nipro Corporation, Hetero and Viatris.
Where is Astellas Pharma headquarters?
Astellas Pharma headquarters is located at 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo.
Where are Astellas Pharma offices?
Astellas Pharma has offices in Tokyo, Takahagi, Takaoka, Toyama and in 57 other locations.
How many offices does Astellas Pharma have?
Astellas Pharma has 64 offices.
Receive alerts for 300+ data fields across thousands of companies